Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more
Genmab AS (GMAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.051x
Based on the latest financial reports, Genmab AS (GMAB) has a cash flow conversion efficiency ratio of 0.051x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Billion) by net assets ($37.18 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genmab AS - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Genmab AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genmab AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Shunwang Tech
SHE:300113
|
0.046x |
|
Werner Enterprises Inc
NASDAQ:WERN
|
0.032x |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
0.108x |
|
Yamada Holdings Co. Ltd
PINK:YMDAF
|
0.019x |
|
NORTH PACIFIC BANK LTD
F:2PT
|
N/A |
|
VEIDEKKE ASA NK 050
F:VK4
|
N/A |
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
XTC New Energy Materials Xiamen Co Ltd
SHG:688778
|
0.026x |
Annual Cash Flow Conversion Efficiency for Genmab AS (2002–2025)
The table below shows the annual cash flow conversion efficiency of Genmab AS from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.18 Billion | $7.56 Billion | 0.203x | -3.92% |
| 2024-12-31 | $36.70 Billion | $7.77 Billion | 0.212x | -9.30% |
| 2023-12-31 | $31.61 Billion | $7.38 Billion | 0.233x | +62.82% |
| 2022-12-31 | $27.28 Billion | $3.91 Billion | 0.143x | +42.85% |
| 2021-12-31 | $22.20 Billion | $2.23 Billion | 0.100x | -70.16% |
| 2020-12-31 | $19.12 Billion | $6.43 Billion | 0.336x | +256.43% |
| 2019-12-31 | $14.05 Billion | $1.33 Billion | 0.094x | -25.45% |
| 2018-12-31 | $8.01 Billion | $1.01 Billion | 0.127x | -50.02% |
| 2017-12-31 | $6.27 Billion | $1.59 Billion | 0.253x | +273.12% |
| 2016-12-31 | $4.83 Billion | $327.72 Million | 0.068x | -23.99% |
| 2015-12-31 | $3.49 Billion | $311.45 Million | 0.089x | +36.87% |
| 2014-12-31 | $2.03 Billion | $132.67 Million | 0.065x | +133.63% |
| 2013-12-31 | $659.52 Million | $-128.00 Million | -0.194x | -204.86% |
| 2012-12-31 | $383.19 Million | $70.92 Million | 0.185x | +120.59% |
| 2011-12-31 | $486.42 Million | $-437.23 Million | -0.899x | -462.02% |
| 2010-12-31 | $1.08 Billion | $268.17 Million | 0.248x | +156.50% |
| 2009-12-31 | $1.30 Billion | $-570.06 Million | -0.439x | -87.36% |
| 2008-12-31 | $2.19 Billion | $-513.33 Million | -0.235x | -233.68% |
| 2007-12-31 | $2.88 Billion | $505.90 Million | 0.175x | +174.30% |
| 2006-12-31 | $1.61 Billion | $-379.62 Million | -0.236x | -26.62% |
| 2005-12-31 | $1.12 Billion | $-208.64 Million | -0.186x | +40.10% |
| 2004-12-31 | $1.18 Billion | $-367.70 Million | -0.311x | -11.87% |
| 2003-12-31 | $1.09 Billion | $-302.36 Million | -0.278x | -26.30% |
| 2002-12-31 | $1.40 Billion | $-308.32 Million | -0.220x | -- |